Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
[fabry disease]
Currently
,
no
method
is
available
to
identify
α-galactosidase
A
(
agalA
)
mutations
determining
clinically
relevant
Fabry
disease
.
In
our
largest
European
Fabry
cohort
,
we
investigated
whether
a
biomarker
,
specific
for
the
defect
,
could
stratify
persons
at
risk
.
A
total
of
124
individuals
with
agalA
mutations
were
investigated
with
a
comprehensive
clinical
workup
,
genetic
analysis
,
and
laboratory
testing
,
including
measurements
of
agalA
activity
and
lyso-
Gb
3
(
degradation
product
of
the
accumulating
Gb
3
)
.
Additionally
,
an
extensive
family
screening
with
a
clinical
workup
of
relatives
was
performed
.
The
patient
population
was
divided
into
2
samples
:
previously
described
mutations
(
n
=
72
)
and
novel
mutations
(
n
=
52
)
.
The
patients
with
previously
described
mutations
were
subdivided
into
2
groups
:
classical
mutations
,
which
were
known
to
cause
the
classic
type
of
Fabry
disease
with
specific
symptoms
and
a
high
risk
for
major
events
in
all
3
main
organs
(
heart
,
kidney
,
and
central
nervous
system
)
,
and
atypical
mutations
without
the
typical
presentation
.
All
patients
with
atypical
mutations
(
n
=
17
)
had
lower
lyso-
Gb
3
levels
than
any
of
the
patients
with
classical
Fabry
disease
(
n
=
55
)
.
A
cutoff
value
of
2
.
7
ng
/
mL
separated
the
2
groups
.
Six
out
of
52
patients
with
novel
mutations
showed
a
lyso-
Gb
3
level
<
2
.
7
ng
/
mL
.
Clinical
investigation
,
blinded
to
lyso-
Gb
3
results
,
revealed
no
classic
organ
involvement
in
these
patients
or
their
relatives
.
In
contrast
,
the
characterization
of
patients
with
lyso-
Gb
3
≥
2
.
7
ng
/
mL
suggested
classical
Fabry
mutations
in
most
of
the
patients
(
93
%
)
.
Our
data
show
that
the
biomarker
lyso-
Gb
3
may
identify
the
clinically
relevant
agalA
mutations
leading
to
Fabry
disease
.
Diseases
Validation
Diseases presenting
"central nervous system"
symptom
22q11.2 deletion syndrome
adrenomyeloneuropathy
alexander disease
aniridia
aromatase deficiency
canavan disease
child syndrome
classical phenylketonuria
congenital toxoplasmosis
cowden syndrome
cushing syndrome
cystinuria
dracunculiasis
erdheim-chester disease
fabry disease
gm1 gangliosidosis
hereditary cerebral hemorrhage with amyloidosis
hirschsprung disease
hodgkin lymphoma, classical
kabuki syndrome
kallmann syndrome
kindler syndrome
krabbe disease
lamellar ichthyosis
legionellosis
liposarcoma
malignant atrophic papulosis
monosomy 21
neonatal adrenoleukodystrophy
phenylketonuria
proteus syndrome
scrub typhus
severe combined immunodeficiency
sneddon syndrome
triple a syndrome
von hippel-lindau disease
waldenström macroglobulinemia
well-differentiated liposarcoma
wiskott-aldrich syndrome
wolf-hirschhorn syndrome
x-linked adrenoleukodystrophy
zellweger syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom